secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unity Biotechnology, Inc. (—)
CIK:        0001463361
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0000950170-24-044230
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unity Biotech reports FY 2023 net loss $39.9M; Phase 2b ASPIRE DME study upsized to 50 patients
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $43.2M as of Dec 31, 2023; runway into Q3 2025.
- Net loss FY 2023 $39.9M (down from $44.5M in 2022); Q4 net loss $4.3M (down from $7.4M).
- R&D expenses decreased $16.8M to $20.1M in FY 2023 due to completion of BEHOLD/ENVISION studies and headcount reduction.
- Phase 2b ASPIRE study in DME (UBX1325 vs aflibercept) upsized to 50 patients; 16-week data expected Q4 2024, 24-week data Q1 2025.
- Published research in Nature Medicine in Jan 2024 on targeting cellular senescence in DME.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1463361/000095017024044230/0000950170-24-044230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1463361/000095017024044230/ubx-20240415.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-044230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer